Treace Medical Concepts Inc

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Biotech & Genomic Medicine▲

Boundless Bio, Monopar, Galectin Lead Biotech Gainers on Pipeline Advances

Several biotech stocks surged on Tuesday, led by Boundless Bio which agreed to an all-stock merger with privately held Serapha Bio. Boundless Bio expects to declare a cash dividend to pre-merger stockholders before the deal closes in the fourth quarter of 2026, after which the combined company will operate as Serapha Bio and trade on Nasdaq under the ticker AATD. Monopar Therapeutics rose over 19% with its New Drug Application for ALXN1840 in Wilson disease on track for mid-2026 submission to the FDA. Galectin Therapeutics gained over 11% after reaching an agreement with the FDA on key elements of its planned Phase 3 program for Belapectin in MASH cirrhosis with portal hypertension, with the final protocol expected in the third quarter of 2026. Other notable movers included Jade Biosciences, up nearly 13% amid progress in its autoimmune pipeline, and Treace Medical Concepts, up almost 12% following the first surgical use of its HyperPlate XM implant.

BOLD ▲GALT ▲JBIO ▲MNPR ▲TMCI ▲

Biotech & Genomic Medicine ▲

RTTNews·64dRead more ▾